Reports Q3 revenue $134.3M, consensus $131.3M. “Our third quarter results demonstrate strong execution and patient focus across the business. We are seeing continued positive traction with our most recent product launches, including our AtriClip platform and cryoSPHERE devices, coupled with durable momentum from expanding adoption of our EnCompass clamp,” said Michael Carrel, President and Chief Executive Officer at AtriCure (ATRC). “As we invest in product innovation and clinical science to build catalysts for the future, we are determined to drive exceptional financial performance, underscored by continued growth and increasing profitability.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC:
- AtriCure enrolls first patient in BoxX-NoAF clinical trial
- AtriCure’s Ongoing Study: Implications for Cardiac Treatment and Market Performance
- AtriCure’s Cryoablation Study: A New Frontier in Pain Management
- AtriCure’s TRAC-AF Registry: A Closer Look at Ongoing Clinical Study
- AtriCure’s BoxX-NoAF Trial: A Step Forward in Cardiac Surgery Innovation